Phase 2 RCT: Donanemab in early Alzheimer’s Disease

Donanemab in Early Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Experimental Alzheimer’s drug could slow cognitive decline in patients, early results suggest – CNN AND Alzheimer’s study shows mixed results for Lilly’s donanemab on secondary outcomes – First World Pharma

Commentary on Twitter

In a phase 2 trial, patients with early Alzheimer’s disease who received donanemab, an antibody that targets amyloid deposits, showed a better composite score for cognition & ability to perform activities of daily living at 76 weeks than those who received placebo. #ADPD2021

— NEJM (@NEJM) March 13, 2021